Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA)

• Published in: Brazilian journal of medical and biological research Vol. 42; no. 10; pp. 963 - 967
• Main Authors: Zhao, W.P., Zhang, Z.G., Li, X.D., Yu, D., Rui, X.F., Li, G.H., Ding, G.Q.
• Format: Journal Article
• Language: English
• Published: Brazil Associação Brasileira de Divulgação Científica 01.10.2009
• Subjects: Adolescent; Adult; BIOLOGY; Celecoxib; Chronic Disease; Chronic pelvic pain syndrome; Cyclooxygenase 2 Inhibitors - therapeutic use; Cyclooxygenase inhibitors; Humans; Male; MEDICINE, RESEARCH & EXPERIMENTAL; Middle Aged; Pain Measurement; Pelvic Pain - drug therapy; Pilot Projects; Prostatitis; Pyrazoles - therapeutic use; Severity of Illness Index; Sulfonamides - therapeutic use; Syndrome; Treatment Outcome; Young Adult; Chronic pelvic pain syndrome; Cyclooxygenase inhibitors; Prostatitis
• DOI: 10.1590/S0100-879X2009005000021
• ISSN: 0100-879X; 1414-431X

We investigated the effectiveness of celecoxib in reducing symptoms in patients with difficult chronic pelvic pain syndrome (CPPS), NIH category IIIA. Sixty-four patients with category IIIA CPPS were randomized into two groups of 32 subjects each. One group was treated with celecoxib (200 mg daily) and the other with placebo. All patients underwent treatment for 6 weeks and were evaluated clinically before (baseline) and after 1, 2, 4, 6, and 8 weeks of treatment. The evaluation included the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and a subjective global assessment (SGA). Repeated measures analysis of variance was used to evaluate treatment and time effects and their interaction. A decrease (means +/- SD) in total NIH-CPSI score from 23.91 +/- 5.27 to 15.88 +/- 2.51 in the celecoxib group and from 24.25 +/- 5.09 to 19.50 +/- 2.50 in the placebo group was observed during treatment (0 to 6 weeks). A statistically significant decrease was observed in pain subscore (P < 0.006), quality of life subscore (P < 0.032) and total NIH-CPSI score (P < 0.015) after 2, 4 and 6 weeks, but not in urinary subscore. In addition, 38% of the celecoxib and 13% of the placebo subjects had at least a moderate improvement in SGA. The trend was similar for the NIH-CPSI scores. However, the response to treatment in terms of total NIH-CPSI score or subscore was not significantly different from placebo after interruption of treatment for 2 weeks. Our results show that celecoxib provides significant symptomatic improvement limited to the duration of the therapy in patients with difficult category IIIA CPPS compared to placebo.